Management imo held off on the ROW launch in favour of the US to set a benchmark in price and then the ROW price would be set off that. Makes sense to me as the US was by prescription. The fact that the FDA has thrown a spanner in the works means the ROW launch has had to be bought forward. Not the ideal scenario. I’m very interested to see what Fleurstat will sell for. Gltah
Management imo held off on the ROW launch in favour of the US to...
-
- There are more pages in this discussion • 15 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add SPL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
10.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $43.82M | |||
| Open | High | Low | Value | Volume |
| 10.5¢ | 11.5¢ | 10.0¢ | $110.6K | 1.006M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 83046 | 10.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 11.0¢ | 30000 | 1 |
View Market Depth
| Last trade - 16.10pm 15/11/2024 (20 minute delay) ? |
| SPL (ASX) Chart |
